The forecast for Renin-Angiotensin System medicine sales in Canada shows a declining trend from 2024 to 2028, decreasing from 1.8% to 0.6% of total sales. This suggests a significant downward shift compared to the previous years, where 2023 stood as the baseline. The year-on-year variation reflects a progressive decline, signaling a potential decrease in market relevance or increased competition from alternative treatments. Over the five-year period, the compound annual growth rate (CAGR) indicates an average decrease in sales, emphasizing a contraction in this segment.
Future trends to watch for include advancements in alternative therapies, shifts in healthcare regulations, and changes in prescription practices that could further impact Renin-Angiotensin System medicine sales. Additionally, patient preferences for newer treatment modalities could influence future market dynamics.
